The good, the (not so) bad and the ugly of immune homeostasis in melanoma

Jessica da Gama Duarte, Katherine Woods, Miles C. Andrews, Andreas Behren

Research output: Contribution to journalReview ArticleResearchpeer-review

4 Citations (Scopus)


Within the immune system multiple mechanisms balance the need for efficient pathogen recognition and destruction with the prevention of tissue damage by excessive, inappropriate or even self-targeting (auto)immune reactions. This immune homeostasis is a tightly regulated system which fails during tumor development, often due to the hijacking of its essential self-regulatory mechanisms by cancer cells. It is facilitated not only by tumor intrinsic properties, but also by the microbiome, host genetics and other factors. In certain ways many cancers can therefore be considered a rare failure of immune control rather than an uncommon or rare disease of the tissue of origin, as the acquisition of potentially oncogenic traits through mutation occurs constantly in most tissues during proliferation. Normally, aberrant cells are well-controlled by cell intrinsic (repair or apoptosis) and extrinsic (immune) mechanisms. However, occasionally oncogenic cells survive and escape control. Melanoma is one of the first cancer types where treatments aimed at restoring and enhancing an immune response to regain control over the tumor have been used with various success rates. With the advent of “modern” immunotherapeutics such as anti-CTLA-4 or anti-PD-1 antibodies that both target negative immune-regulatory pathways on immune cells resulting in durable responses in a proportion of patients, the importance of the interplay between the immune system and cancer has been established beyond doubt.

Original languageEnglish
Pages (from-to)497-506
Number of pages10
JournalImmunology and Cell Biology
Issue number5
Publication statusPublished - May 2018
Externally publishedYes


  • Immune homeostasis
  • immunotherapy
  • melanoma

Cite this